News Quantified

AKTS – aktis oncology, inc. - common stock (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Aktis Oncology (AKTS) had its price target raised by HC Wainwright from $30.00 to $33.00. They now have a "buy" rating on the stock.

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Aktis Oncology (AKTS) is now covered by HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.

Aktis Oncology to Present at Upcoming March Investor Conferences

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Leerink Partners

JPMorgan Chase & Co.

Leerink Partners

Top News Gainers

5/7 Akoustis Technologies to Attend the 4th Annual Oppenheimer Emerging Growth Conference on May 14, 2019 20.3%

7/10 Akoustis Expects June Quarter Revenue at Upper End of Previous Guidance 18.0%

4/21 Form 8-K Akoustis Technologies, For: Apr 17 15.8%

12/11 Form 424B5 Akoustis Technologies, 14.2%

4/3 Form 4 Akoustis Technologies, For: Apr 01 Filed by: Shealy Jeffrey B. 11.2%

4/8 Akoustis Announces First 5G Network Infrastructure Design Win with Tier-1 OEM 10.6%

8/26 Akoustis Technologies Inc (NASDAQ: AKTS) was given a new $7.00 price target on by analysts at Northland Securities. They now have a "buy" rating on the stock. 9.7%

11/8 Akoustis Ships 60,000 Pre-Production 5.6 GHz WiFi Filters to Leading RF Customer 9.2%

5/10 Q3/2019 3/31/2019 EPS -0.310 ZacksConsensus N/A ActVsEst N/A - N/A 9.1%

1/6 Form 4 Akoustis Technologies, For: Jan 06 Filed by: Denbaars Steven 6.9%

Top News Decliners

2/3 Akoustis Announces First Commercial Volume Order for 5G Infrastructure RF Filters -10.0%

3/17 Form 4 Akoustis Technologies, For: Mar 13 Filed by: Houlden Rohan -8.3%

11/6 Form 4 Akoustis Technologies, For: Nov 04 Filed by: NEAL JERRY D -6.3%

12/17 Akoustis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares -6.2%

4/15 Form 4 Akoustis Technologies, For: Apr 13 Filed by: McMahon Jeffrey -5.9%

5/17 Form 4 Akoustis Technologies, For: May 17 Filed by: Aichele David -4.7%

11/5 Akoustis Technologies Inc (NASDAQ: AKTS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.5%

11/6 Akoustis to Webcast Investor Update Call November 8th at 8:00 a.m. EDT -4.4%

7/10 Form 4 Akoustis Technologies, For: Jul 08 Filed by: Denbaars Steven -4.1%

11/13 Akoustis Technologies Inc (NASDAQ: AKTS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -3.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day